DOCSLIB.ORG

Regulations for Disease Reporting and Control

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Regulations for Disease Reporting and Control Department of Health Regulations for Disease Reporting and Control Commonwealth of Virginia State Board of Health November 2018* Virginia Department of Health Office of Epidemiology 109 Governor Street P.O. Box 2448 Richmond, VA 23218 *Regulation language that has been stricken in 12 VAC 5-90-90 of this document represents proposed regulatory changes that have been moved to 12 VAC 5-90-80. This resulted from separate regulatory changes that have progressed using different processes at differing timelines. Department of Health Department of Health TABLE OF CONTENTS Part I. DEFINITIONS ........................................................................................................... 1 12 VAC 5-90-10. Definitions ................................................................................. 1 Part II. GENERAL INFORMATION .................................................................................. 8 12 VAC 5-90-20. Authority ................................................................................... 8 12 VAC 5-90-30. Purpose ...................................................................................... 8 12 VAC 5-90-40. Administration ........................................................................... 8 12 VAC 5-90-70. Powers and Procedures of Chapter Not Exclusive .................... 9 Part III. REPORTING OF DISEASE ................................................................................ 10 12 VAC 5-90-80. Lists of Diseases that Shall be Reported ................................. 10 A. Reportable disease list .............................................................................. 10 B. Conditions reportable by directors of laboratories ................................... 11 C. Reportable diseases requiring rapid communication ................................ 13 D. Submission of initial isolate or other specimen for further public health testing .................................................................................................... 14 E. Neonatal abstinence syndrome ................................................................. 15 F. Outbreaks .................................................................................................. 15 G. Toxic substance-related illnesses ............................................................. 15 H. Unusual occurrence of disease of public health concern ......................... 15 12 VAC 5-90-90. Those Required to Report....................................................... 15 A. Physicians ................................................................................................. 15 B. Directors of laboratories ........................................................................... 16 C. Persons in charge of a medical care facility ............................................. 17 D. Persons in charge of a residential or day program, service, or facility licensed or operated by any agency of the Commonwealth, or a school, child care center, or summer camp ....................................................... 18 E. Local health directors................................................................................ 18 F. Persons in charge of hospitals, nursing facilities or nursing homes, assisted living facilities, and correctional facilities ............................................ 18 G. Employees, applicants, and persons in charge of food establishments .... 19 Part IV. CONTROL OF DISEASE .................................................................................... 19 12 VAC 5-90-100. Methods ................................................................................. 19 i Department of Health 12 VAC 5-90-103. Isolation for Communicable Disease of Public Health Threat .............................................................................................................. 20 A. Application ............................................................................................... 20 B. Documentation.......................................................................................... 21 C. Means of isolation .................................................................................... 21 D. Delivery .................................................................................................... 21 E. Enforcement .............................................................................................. 21 F. Health status monitoring ........................................................................... 22 G. Essential needs .......................................................................................... 22 H. Appeals ...................................................................................................... 22 I. Release from isolation............................................................................... 22 J. Affected area .............................................................................................. 22 12 VAC 5-90-107. Quarantine .............................................................................. 23 A. Application ............................................................................................... 23 B. Documentation.......................................................................................... 23 C. Means of quarantine ................................................................................. 24 D. Delivery .................................................................................................... 24 E. Enforcement .............................................................................................. 24 F. Health status monitoring ........................................................................... 25 G. Essential needs .......................................................................................... 25 H. Appeals ...................................................................................................... 25 I. Release from quarantine ............................................................................ 25 J. Affected area .............................................................................................. 25 Part V. IMMUNIZATION OF PERSONS LESS THAN 18 YEARS OF AGE ............. 26 12 VAC 5-90-110. Dosage and Age Requirements for Immunizations; Obtaining Immunizations ............................................................................... 26 Part VI. VENEREAL DISEASE ........................................................................................ 26 12 VAC 5-90-130. Prenatal Testing ..................................................................... 26 Part VII. PREVENTION OF BLINDNESS FROM OPHTHALMIA NEONATORUM27 12 VAC 5-90-140. Procedure for Preventing Ophthalmia Neonatorum .............. 27 ii Department of Health Part VIII. CANCER REPORTING ................................................................................... 27 12 VAC 5-90-150. Authority ............................................................................... 27 12 VAC 5-90-160. Reportable Cancers and Tumors ........................................... 27 12 VAC 5-90-170. Those Required to Report ..................................................... 27 12 VAC 5-90-180. Report Contents and Procedures ........................................... 27 Part IX. PROTOCOL FOR IDENTIFICATION OF CHILDREN WITH ELEVATED BLOOD LEAD LEVELS .................................................................................... 28 12 VAC 5-90-215. Schedule and Criteria For and Confirmation of Blood Lead Testing and Information to be Provided ........................................................ 28 A. Schedule for Testing ................................................................................. 28 B. Criteria for Testing ................................................................................... 28 C. Exceptions ................................................................................................ 29 D. Confirmation of Blood Lead Levels ......................................................... 29 E. Information to be Provided ....................................................................... 29 Part X. TUBERCULOSIS CONTROL .............................................................................. 29 12 VAC 5-90-225. Additional Data to be Reported Related to Persons with Active Tuberculosis Disease (Confirmed or Suspected) ........................................... 29 Part XI. HUMAN IMMUNODEFICIENCY VIRUS (HIV) TESTING OF GAMETE DONORS .......................................................................................................................... 31 12 VAC 5-90-230. Definitions ............................................................................. 31 12 VAC 5-90-240. Excluding Donors with High Risk Factors ........................... 32 12 VAC 5-90-250. Storage of Semen Pending Negative HIV Tests ................... 32 12 VAC 5-90-260. Use of Ova After Negative HIV Tests .................................. 32 12 VAC 5-90-270. Notifying Recipients of Option to Delay Transfer ................ 33 Part XII. REPORTING OF DANGEROUS MICROBES AND PATHOGENS ........... 33 12 VAC 5-90-280. Reporting of Dangerous Microbes and Pathogens ................ 33 A. Definitions ................................................................................................ 33 B. Administration .........................................................................................
Load more

Recommended publications
  • Small Drinking Water Systems Project
    Strong evidence, stronger public health Small Drinking Water-borne Disease Outbreaks in Water Systems Canadian Small Drinking Water Systems Project Hannah Moffatt, Sylvia Struck Report Highlights Information about Canadian drinking water systems and past water-borne disease outbreaks is incomplete and non-standardized. Standard definitions and coordinated surveillance systems for water-borne disease outbreaks would help inform policy and practice. A relatively high proportion of past water-borne disease outbreaks in Canada are estimated to have occurred in small drinking water systems serving populations of 5,000 people or less. Water-borne disease outbreaks in small drinking water systems are often the result of a combination of water system failures; contributing factors often include a lack of source water protection and inadequate drinking water treatment. Analyses suggest small drinking water systems face challenges associated with infrastructure, technology, and financial constraints. Investments in drinking water systems and operator training have the potential to reduce the burden of water-borne disease in Canada. Executive Summary Generally, Canadians have access to safe and secure drinking water. However, as demonstrated by the events of Walkerton in 2000, the exception can be tragic. Outbreaks of water-borne disease are preventable, yet evidence-informed policy and practice is hampered, in part, by our limited knowledge of drinking water systems that experience outbreaks and the factors that contribute to outbreaks in Canada. There is no national surveillance system for systematic collection of water-borne disease outbreak data. Investigating past water-borne disease outbreaks is a valuable approach to collect information to inform practice and policy. Investigations of water-borne disease outbreaks are challenging because the outbreak events are rare, the pathogenic agents involved may be transmitted via multiple routes (e.g., person to person, food-borne, as well as water-borne), and gastrointestinal illnesses are frequently under-reported.
    [Show full text]
  • Parinaud's Oculoglandular Syndrome
    Tropical Medicine and Infectious Disease Case Report Parinaud’s Oculoglandular Syndrome: A Case in an Adult with Flea-Borne Typhus and a Review M. Kevin Dixon 1, Christopher L. Dayton 2 and Gregory M. Anstead 3,4,* 1 Baylor Scott & White Clinic, 800 Scott & White Drive, College Station, TX 77845, USA; [email protected] 2 Division of Critical Care, Department of Medicine, University of Texas Health, San Antonio, 7703 Floyd Curl Drive, San Antonio, TX 78229, USA; [email protected] 3 Medical Service, South Texas Veterans Health Care System, San Antonio, TX 78229, USA 4 Division of Infectious Diseases, Department of Medicine, University of Texas Health, San Antonio, 7703 Floyd Curl Drive, San Antonio, TX 78229, USA * Correspondence: [email protected]; Tel.: +1-210-567-4666; Fax: +1-210-567-4670 Received: 7 June 2020; Accepted: 24 July 2020; Published: 29 July 2020 Abstract: Parinaud’s oculoglandular syndrome (POGS) is defined as unilateral granulomatous conjunctivitis and facial lymphadenopathy. The aims of the current study are to describe a case of POGS with uveitis due to flea-borne typhus (FBT) and to present a diagnostic and therapeutic approach to POGS. The patient, a 38-year old man, presented with persistent unilateral eye pain, fever, rash, preauricular and submandibular lymphadenopathy, and laboratory findings of FBT: hyponatremia, elevated transaminase and lactate dehydrogenase levels, thrombocytopenia, and hypoalbuminemia. His condition rapidly improved after starting doxycycline. Soon after hospitalization, he was diagnosed with uveitis, which responded to topical prednisolone. To derive a diagnostic and empiric therapeutic approach to POGS, we reviewed the cases of POGS from its various causes since 1976 to discern epidemiologic clues and determine successful diagnostic techniques and therapies; we found multiple cases due to cat scratch disease (CSD; due to Bartonella henselae) (twelve), tularemia (ten), sporotrichosis (three), Rickettsia conorii (three), R.
    [Show full text]
  • Globalization and Infectious Diseases: a Review of the Linkages
    TDR/STR/SEB/ST/04.2 SPECIAL TOPICS NO.3 Globalization and infectious diseases: A review of the linkages Social, Economic and Behavioural (SEB) Research UNICEF/UNDP/World Bank/WHO Special Programme for Research & Training in Tropical Diseases (TDR) The "Special Topics in Social, Economic and Behavioural (SEB) Research" series are peer-reviewed publications commissioned by the TDR Steering Committee for Social, Economic and Behavioural Research. For further information please contact: Dr Johannes Sommerfeld Manager Steering Committee for Social, Economic and Behavioural Research (SEB) UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases (TDR) World Health Organization 20, Avenue Appia CH-1211 Geneva 27 Switzerland E-mail: [email protected] TDR/STR/SEB/ST/04.2 Globalization and infectious diseases: A review of the linkages Lance Saker,1 MSc MRCP Kelley Lee,1 MPA, MA, D.Phil. Barbara Cannito,1 MSc Anna Gilmore,2 MBBS, DTM&H, MSc, MFPHM Diarmid Campbell-Lendrum,1 D.Phil. 1 Centre on Global Change and Health London School of Hygiene & Tropical Medicine Keppel Street, London WC1E 7HT, UK 2 European Centre on Health of Societies in Transition (ECOHOST) London School of Hygiene & Tropical Medicine Keppel Street, London WC1E 7HT, UK TDR/STR/SEB/ST/04.2 Copyright © World Health Organization on behalf of the Special Programme for Research and Training in Tropical Diseases 2004 All rights reserved. The use of content from this health information product for all non-commercial education, training and information purposes is encouraged, including translation, quotation and reproduction, in any medium, but the content must not be changed and full acknowledgement of the source must be clearly stated.
    [Show full text]
  • Water-Borne Diseases
    Bronx Community Health Dashboard: Communicable Disease Last Updated: 9/24/2019 See last slide for more information about this project. 1 Food- & Water-Borne Diseases Data note: All data are reported by labs and are not a measure of true incidence in the population as not all people seek care or are tested. 2 Overall, salmonella rates have declined in all five boroughs Bronx Brooklyn Manhattan Queens Staten Island 25 Salmonella is a group of bacteria that is one of the most common causes of food poisoning in the U.S. Most infected people develop diarrhea, fever, and abdominal cramps 12 to 72 hours after infection. The illness 20 typically lasts 4 to 7 days, and most people recover without treatment. However, in some people, the diarrhea may be so severe that they need to be hospitalized. 16.0 16.2 15 15.5 13.5 12.6 13.1 12.3 10 10.1 adjusted rate per adjusted 100,000 Salmonella 7.0 - Age 5 0 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 3 Data source: New York City Department of Health and Mental Hygiene Communicable Disease Surveillance Data, 2000-2017. Salmonella rates are above average in the Morrisania, Pelham, and Fordham areas of the Bronx compared to New York City overall 101 101 Kingsbridge 103 102 16 15.5 102 Northeast Bronx 14.4 13.9 103 Fordham 105 104 12.8 104 Pelham 106 105 Crotona 107 12 106 Morrisania 10.3 10.1 107 Mott Haven 8.8 8 4 adjusted rate per adjusted 100,000 Salmonella - 0 Age 4 Data source: New York City Department of Health and Mental Hygiene Communicable Disease Surveillance Data, 2017.
    [Show full text]
  • Reportable Diseases and Conditions
    KINGS COUNTY DEPARTMENT of PUBLIC HEALTH 330 CAMPUS DRIVE, HANFORD, CA 93230 REPORTABLE DISEASES AND CONDITIONS Title 17, California Code of Regulations, §2500, requires that known or suspected cases of any of the diseases or conditions listed below are to be reported to the local health jurisdiction within the specified time frame: REPORT IMMEDIATELY BY PHONE During Business Hours: (559) 852-2579 After Hours: (559) 852-2720 for Immediate Reportable Disease and Conditions Anthrax Escherichia coli: Shiga Toxin producing (STEC), Rabies (Specify Human or Animal) Botulism (Specify Infant, Foodborne, Wound, Other) including E. coli O157:H7 Scrombroid Fish Poisoning Brucellosis, Human Flavivirus Infection of Undetermined Species Shiga Toxin (Detected in Feces) Cholera Foodborne Disease (2 or More Cases) Smallpox (Variola) Ciguatera Fish Poisoning Hemolytic Uremic Syndrome Tularemia, human Dengue Virus Infection Influenza, Novel Strains, Human Viral Hemorrhagic Fever (Crimean-Congo, Ebola, Diphtheria Measles (Rubeola) Lassa, and Marburg Viruses) Domonic Acid Poisoning (Amnesic Shellfish Meningococcal Infections Yellow Fever Poisoning) Novel Virus Infection with Pandemic Potential Zika Virus Infection Paralytic Shellfish Poisoning Plague (Specify Human or Animal) Immediately report the occurrence of any unusual disease OR outbreaks of any disease. REPORT BY PHONE, FAX, MAIL WITHIN ONE (1) WORKING DAY Phone: (559) 852-2579 Fax: (559) 589-0482 Mail: 330 Campus Drive, Hanford 93230 Conditions may also be reported electronically via the California
    [Show full text]
  • WO 2014/134709 Al 12 September 2014 (12.09.2014) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2014/134709 Al 12 September 2014 (12.09.2014) P O P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 31/05 (2006.01) A61P 31/02 (2006.01) kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, (21) International Application Number: BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, PCT/CA20 14/000 174 DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (22) International Filing Date: HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, 4 March 2014 (04.03.2014) KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, (25) Filing Language: English OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, (26) Publication Language: English SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, (30) Priority Data: ZW. 13/790,91 1 8 March 2013 (08.03.2013) US (84) Designated States (unless otherwise indicated, for every (71) Applicant: LABORATOIRE M2 [CA/CA]; 4005-A, rue kind of regional protection available): ARIPO (BW, GH, de la Garlock, Sherbrooke, Quebec J1L 1W9 (CA). GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, (72) Inventors: LEMIRE, Gaetan; 6505, rue de la fougere, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, Sherbrooke, Quebec JIN 3W3 (CA).
    [Show full text]
  • 2012 Case Definitions Infectious Disease
    Arizona Department of Health Services Case Definitions for Reportable Communicable Morbidities 2012 TABLE OF CONTENTS Definition of Terms Used in Case Classification .......................................................................................................... 6 Definition of Bi-national Case ............................................................................................................................................. 7 ------------------------------------------------------------------------------------------------------- ............................................... 7 AMEBIASIS ............................................................................................................................................................................. 8 ANTHRAX (β) ......................................................................................................................................................................... 9 ASEPTIC MENINGITIS (viral) ......................................................................................................................................... 11 BASIDIOBOLOMYCOSIS ................................................................................................................................................. 12 BOTULISM, FOODBORNE (β) ....................................................................................................................................... 13 BOTULISM, INFANT (β) ...................................................................................................................................................
    [Show full text]
  • Bioterrorism Diseases Annex Infectious Disease Emergency Response (IDER) Plan
    Bioterrorism Diseases Annex Infectious Disease Emergency Response (IDER) Plan Contents I Background IV Activation & Notification II Response Organization V Operational Guidance III Purpose & Objectives VI Resources I. BACKGROUND A bioterrorism event is defined for the purposes of this annex as the deliberate introduction of pathogenic microorganisms or their products (bacteria, viruses, fungi or toxins) into a community. Potential bioterrorism agents are categorized by the Centers for Disease Control and Prevention (CDC) by category. Category A agents (highest priority) include organisms that pose a risk to national security because they can be easily disseminated or transmitted from person-to-person; result in high mortality rates and have the potential for major public health impact; might cause public panic and social disruption; and require special action for public health preparedness. These include: • Anthrax (Bacillus anthracis) • Smallpox (variola major) • Botulism (Clostridium botulinum • Tularemia (Franciscella tularensis) toxin) • Viral Hemorrhagic Fevers (filoviruses, • Plague (Yersinia pestis) arenaviruses) Of second highest priority are category B agents which are organisms that are moderately easy to disseminate; that result in moderate morbidity rates and low mortality rates; and that require enhanced diagnostic capacity and disease surveillance. • Brucellosis (Brucella species)* • Epsilon toxin of Clostridium perfringens • Food safety threats (Salmonella species, Escherichia coli O157:H7, Shigella) • Glanders (Burkholderia
    [Show full text]
  • Reportable Disease Surveillance in Virginia, 2013
    Reportable Disease Surveillance in Virginia, 2013 Marissa J. Levine, MD, MPH State Health Commissioner Report Production Team: Division of Surveillance and Investigation, Division of Disease Prevention, Division of Environmental Epidemiology, and Division of Immunization Virginia Department of Health Post Office Box 2448 Richmond, Virginia 23218 www.vdh.virginia.gov ACKNOWLEDGEMENT In addition to the employees of the work units listed below, the Office of Epidemiology would like to acknowledge the contributions of all those engaged in disease surveillance and control activities across the state throughout the year. We appreciate the commitment to public health of all epidemiology staff in local and district health departments and the Regional and Central Offices, as well as the conscientious work of nurses, environmental health specialists, infection preventionists, physicians, laboratory staff, and administrators. These persons report or manage disease surveillance data on an ongoing basis and diligently strive to control morbidity in Virginia. This report would not be possible without the efforts of all those who collect and follow up on morbidity reports. Divisions in the Virginia Department of Health Office of Epidemiology Disease Prevention Telephone: 804-864-7964 Environmental Epidemiology Telephone: 804-864-8182 Immunization Telephone: 804-864-8055 Surveillance and Investigation Telephone: 804-864-8141 TABLE OF CONTENTS INTRODUCTION Introduction ......................................................................................................................................1
    [Show full text]
  • HIV (Human Immunodeficiency Virus)
    TABLE OF CONTENTS AFRICAN TICK BITE FEVER .........................................................................................3 AMEBIASIS .....................................................................................................................4 ANTHRAX .......................................................................................................................5 ASEPTIC MENINGITIS ...................................................................................................6 BACTERIAL MENINGITIS, OTHER ................................................................................7 BOTULISM, FOODBORNE .............................................................................................8 BOTULISM, INFANT .......................................................................................................9 BOTULISM, WOUND .................................................................................................... 10 BOTULISM, OTHER ...................................................................................................... 11 BRUCELLOSIS ............................................................................................................. 12 CAMPYLOBACTERIOSIS ............................................................................................. 13 CHANCROID ................................................................................................................. 14 CHLAMYDIA TRACHOMATIS INFECTION .................................................................
    [Show full text]
  • Principles and Practice of Public Health Surveillance
    r I P82 " ,Ji<liTin' S PB93-101129 1994 I" PRINCIPLES AND PRACTICE OF PUBLIC HEALTH SURVEILLANCE CENTERS FOR DISEASE CONTROL ATLANTA, GA AUG 92 U.S. DEPARTMENT OF COMMERCE National Technical Information Service \\ P3S3-1C112S Principles and Practice of Public Health Surveillance Steven M. Teutsch R. Elliott Churchill Editors BLDG 10 S. DEPARTMENT OF HEALTH & HUMAN SERVICES CDC Public Health Service Health Lftwy Paiuam »*» Epidemiology Program Office Lane.P.n".. 5600 Fishars Centers for Disease Control 20857 August 1992 Us* of trade naaaa is for identification only and does not constitute endorsement by the Public Health Service or the Centers for Disease Control. Form Approved REPORT DOCUMENTATION PAGE OMB No. 0704-0188 Public reporting burden for this collection of information is estimated to average 1 hour oer response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information Send comments regarding this burden estimate or any other aspect of this 5 collection of information, including suggestions for reducing this burden, to Washington Headouarters Services. Directorate for Information Operations and Reports, 1215 Jefferson L ' " *— Dav — '. andto the Officeof Managementand Budget. Paperwork Reduction Project (0704-0188), Washington. DC 20503 PB9 3-10 1129 2. REPORT DATE 3. REPORT TYPE AND DATES COVERED August 1992 Final 4. TITLE AND SUBTITLE 5. FUNDING NUMBERS Principles and Practice of Surveillance None 6. AUTHOR(S) Teutsch, Steven M. and CHoif.) 4il-^^o Churchill, R. Elliott, Editors 7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) 8. PERFORMING ORGANIZATION REPORT NUMBER Epidemiology Program Office Centers for Disease Control Mail stop C08 Atlanta, GA 30333 None 9.
    [Show full text]
  • Whole Day Download the Hansard
    Tuesday Volume 597 30 June 2015 No. 25 HOUSE OF COMMONS OFFICIAL REPORT PARLIAMENTARY DEBATES (HANSARD) Tuesday 30 June 2015 £5·00 © Parliamentary Copyright House of Commons 2015 This publication may be reproduced under the terms of the Open Parliament licence, which is published at www.parliament.uk/site-information/copyright/. 1315 30 JUNE 2015 1316 Robert Flello (Stoke-on-Trent South) (Lab): I draw House of Commons attention to my entry in the register of interests. Many small and medium-sized freight businesses struggle with Tuesday 30 June 2015 the cost of training drivers. Have the Government any plans to look at this afresh with a view to helping people train to become lorry drivers in the UK? The House met at half-past Eleven o’clock Sajid Javid: As the hon. Gentleman will know, it is PRAYERS very important for the Government to listen to all industries about their skills and training needs, including for freight drivers. Of course, the option of apprenticeships [MR SPEAKER in the Chair] is open to that industry, but we must look at other measures too. BUSINESS BEFORE QUESTIONS Mike Wood (Dudley South) (Con): The business rates system is one of the major barriers to competitiveness CONTINGENCIES FUND 2014-15 for small and medium-sized enterprises. What plans do Ordered, Ministers have to reform and alleviate some of that That there be laid before this House an Account of the burden? Contingencies Fund, 2014–15, showing– (1) a Statement of Financial Position; Sajid Javid: My hon. Friend will know that the (2) a Statement of Cash Flows; and Chancellor announced a full review of business rates in (3) Notes to the Account; together with the Certificate and the last Budget.
    [Show full text]